Lek opens a new representative office in Riga, Latvia
Riga, 20 June -Today, Lek opened its new representative office in Riga, Latvia. This is one of the representative offices in the Baltic states, representing Lek’s 25th unit abroad. The opening ceremony was attended by eminent representatives of economy and politics in Latvia.
Lek is an internationally operating company, marketing its products in more than 80 countries. In line with its strategy, Lek is consolidating its position in certain key markets with an increasingly strong marketing and sales presence.
In the Baltic region, Lek has been marketing its comprehensive product range for more than 30 years. Last year it opened a representative office in Vilnius, Lithuania. Initially, the marketing product portfolio in Latvia was identical to that in the Russian Federation and other states of the former Soviet Union. When our medical representatives’ teams started to operate in Latvia, local marketing features began to be recognized, later on influencing the new portfolio formation.
In Latvia, the pharmaceutical market trends are identical to those in the entire Baltics region (the size of the Latvian pharmaceutical market is approx. 120 million USD), showing oscillations, yet this area is interesting due to the presence of all the multinational companies in the Baltic region.. Lek’s share in Latvia accounts for 1.6% of the total Latvian pharmaceutical market; however, the Latvian pharmaceutical market is of key importance for the consolidation of Lek’s position in the Baltic region.
One of Lek’s most successful products in the Latvian market is Amoksiklav, a broad-spectrum antibiotic, used in the treatment of infections in children and adults. Amoksiklav, the combination of amoxycillin and clavulanic acid, ranks among the fifteen best selling drugs worldwide, and is the top-selling antibiotic. This confirms that the Amoksiklav therapy is one of the most advanced and safest antibiotic therapies across the world. In the Latvian market the total market share of six key products accounts for 85% of total Lek’s sales in this market.
With an advanced and high quality technology of drug manufacture, Lek assures the quality in conformity with all the global standards. For all its markets Lek provides the same quality of products at competitive prices. The company places the greatest emphasis on the pharmaco-economics of its drugs, which is equally important for both the patient and the country itself. On the basis of the modern medical doctrine and through greater efficacy of treatment and fewer side effects, it contributes to a higher quality of people’s lives, while at the same time reducing the cost of therapy.
In Latvia, Lek is currently employing 10 medical representatives, while in line with expanding its sales and marketing activities, it is planning to recruit more staff in this field.